Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID NAPRAPAC 500 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID NAPRAPAC 500 COPACKAGED.
PANTOPRAZOLE SODIUM vs PREVACID NAPRAPAC 500 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination